PDE4B and idiopathic pulmonary fibrosis: The FIBRONEER trial of nerandomilast in IPF demonstrated efficacy of PDE4B inhibition, becoming the first positive phase III RCT in IPF in a decade.114Currently, two other medications (treprostinil and admilparant) are under investigation in phase III RCTs.